trial

Long-term Study of DSP-5423P in Patients With Schizophrenia

NCTId NCT02335658
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 200 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2017-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
200 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-12
Primary completion
2017-05
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
DSP-5423P

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Investigators

1
Director, Drug Development DivisionStudy Director

Sites

1 total
Tokyo, Japan

Linked catalysts

1
Long-term Study of DSP-5423P in Patients With Schizophrenia — primary completion2017-05

Facts & assertions

4 sourced
Enrollment
200
Phase
PHASE3
Primary Completion Date
2017-05
Status
COMPLETED
relationships
The graph out of here
drug
DSP-5423P
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Director, Drug Development Division
person